Daily Archives: 4th September 2018

CORD I phase III clinical trial outcomes of XIAFLEX published Auxilium Pharmaceuticals.

Today’s publication contains stratified results of the analysis on a joint by joint basis and by severity of the diseased joint. Significant results include: ‘Dupuytren’s cords could become disabling at an early on stage of contracture and can significantly impact many aspects of individuals’ daily lives,’ stated Dr. Tony DelConte, Chief Medical Officer for Auxilium. ‘We believe these brand-new data will be well-received by the doctor and patient community who have expressed a need for an alternative treatment option to the current requirements of observation and, ultimately, surgery treatment.’ Related StoriesDeaths from avoidable risk factors: an interview with Dr Ali Mokdad, IHMEAddressing quality of life needs in prostate cancers: an interview with Professor Louis DenisIdentifying obstructive coronary artery disease in women: an interview with Dr. Continue reading